These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 15889063)

  • 21. Evaluating the safety of diabetes drugs: perspective of a Food and Drug Administration insider.
    Misbin RI
    Diabetes Care; 2005 Oct; 28(10):2573-6. PubMed ID: 16186303
    [No Abstract]   [Full Text] [Related]  

  • 22. Challenges in evaluating cancer as a clinical outcome in postapproval studies of drug safety.
    Pinheiro SP; Rivera DR; Graham DJ; Freedman AN; Major JM; Penberthy L; Levenson M; Bradley MC; Wong HL; Ouellet-Hellstrom R
    Ann Epidemiol; 2016 Nov; 26(11):735-740. PubMed ID: 27663208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Inclusion of Studies Identified by the FDA as Having Falsified Data in the Results of Meta-analyses: The Example of the Apixaban Trials.
    Garmendia CA; Nassar Gorra L; Rodriguez AL; Trepka MJ; Veledar E; Madhivanan P
    JAMA Intern Med; 2019 Apr; 179(4):582-584. PubMed ID: 30830216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Past, Present, and Future of Drug-Drug Interactions.
    Levy RH; Ragueneau-Majlessi I
    Clin Pharmacol Ther; 2019 Jun; 105(6):1286-1288. PubMed ID: 30773619
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pharmacological review for drug approval].
    Nishioka K
    Nihon Yakurigaku Zasshi; 2013 Mar; 141(3):155-9. PubMed ID: 23470481
    [No Abstract]   [Full Text] [Related]  

  • 26. Two-stage drug approval would reduce the risks.
    Frantz JA
    Nature; 2005 May; 435(7039):143. PubMed ID: 15889063
    [No Abstract]   [Full Text] [Related]  

  • 27. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postmarketing surveillance and reporting of adverse drug events.
    Baer RK
    S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
    [No Abstract]   [Full Text] [Related]  

  • 29. Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
    Green DJ; Sun H; Burnham J; Liu XI; van den Anker J; Temeck J; Yao L; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2019 Mar; 105(3):555-557. PubMed ID: 30094815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How can we regulate medicines better?
    Garattini S; Bertele' V
    BMJ; 2007 Oct; 335(7624):803-5. PubMed ID: 17947785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Faster evaluation of vital drugs.
    Kessler DA; Feiden KL
    Sci Am; 1995 Mar; 272(3):48-54. PubMed ID: 7871409
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.